The Second Circuit revived an antitrust case Wednesday against AstraZeneca Plc and three other pharmaceutical firms, saying ...

On Wednesday, Novavax Inc. (NASDAQ:NVAX) reported second-quarter 2025 sales of $239.24 million, compared to $415 million a year ago, beating the consensus of $156.29 million. The company completed the ...

Digitization has allowed Sanofi to optimize manufacturing and automate document preparation. And now, the firm predicts that ...

Novavax on Wednesday raised its full-year revenue forecast as it received a $175 million milestone payment from Sanofi ...

The Department of Health and Human Services is terminating around $500 million in BARDA contracts associated with mRNA ...

Novavax, Inc. (Nasdaq: NVAX) today announced its financial results and operational highlights for the second quarter ended ...

The US Department of Health and Human Services has planned to cancel $500 million in funding for mRNA vaccines, citing ...

Novavax raised its full-year adjusted revenue forecast on Wednesday, banking on higher sales tied to its vaccine supply ...

AI research is central to many of the deals. In April, French pharmaceutical giant Sanofi announced a $1.7 billion agreement ...

Resting-state EEG (RS-EEG) has emerged as a non-invasive, low-cost tool for Alzheimer’s disease (AD) diagnosis and ...

Converging evidence supports a key pathogenic role of the glymphatic system in the accumulation of pathological aggregates in ...

The Spain-based CDMO strengthens its North American presence and capabilities through its purchase, while also acquiring a ...